Fig. 4
From: Defective transcription elongation in a subset of cancers confers immunotherapy resistance
TEdeff correlates with clinical resistance to immunotherapy. a Kaplan–Meier survival curves of TEdeff and TEprof KIRC patients. Left: all patients with treatment data, right: those that received immunotherapy (IL2 and IFN), b Kaplan–Meier survival curves of TEprof and TEdeff patients treated with immunotherapy or targeted therapy. c Same as in a in SKCM patients. Middle: patients treated with immunotherapy other than immune checkpoint inhibitors, right: patients that received immune checkpoint inhibitor therapy. d Left: percentage of therapy responders among TEdeff and TEprof subset of the Van Allen et al cohort, right: progression-free and overall survival curves of TEdeff and TEprof samples in this cohort, e Left: percentage of responders among TEdeff and TEprof subset in the Hugo et al. cohort, right: Kaplan–Meier curves for OS in TEdeff and TEprof patients, f overall survival curves of patients in the Hugo cohort stratified based on TEdeff and the non-synonymous mutational burden (NMB), g Kaplan–Meier curves of OS and PFS in the Van Allen cohort stratified according to TEdeff and TIL status. The p-values in survival analyses reflect Wald test, and in the barplots Fisher’s exact test
